HC Boutique Analyst Prospects

Goin into my SA at a growing HC boutique. Been seeing a lot of stuff around here how this path is basically a banking career. How true is this? What are some prospects post biotech banking?

Also, how hard would it be get into the s tier HC (CVP, EVR, GS, Dyal) banking after or during my analyst years?

4 Comments
 

Based on the most helpful WSO content, here's what you need to know:

  1. Prospects Post-Biotech Banking:
    Biotech and healthcare (HC) investment banking can open up a variety of exit opportunities. Analysts in this space often transition to roles in venture capital (VC), private equity (PE), hedge funds (HF), or even operational roles at biotech startups. For example, some professionals move into VC firms that focus on life sciences or biopharma, where they can leverage their industry expertise. Others may join HFs or PE firms with a healthcare focus, or even take on strategic roles in biotech companies.

  2. Transitioning to Top-Tier HC Banks (CVP, EVR, GS, Dyal):
    Moving from a growing HC boutique to top-tier HC banks like Centerview Partners (CVP), Evercore (EVR), Goldman Sachs (GS), or Dyal Capital is challenging but not impossible. Success depends on several factors:

    • Deal Experience: Strong deal flow and exposure to significant transactions at your boutique will be critical. Highlighting biotech M&A or capital markets experience can make you stand out.
    • Networking: Building relationships with professionals at these firms is essential. Networking through alumni, industry events, or even LinkedIn can help you get on their radar.
    • Skill Development: Ensure you develop strong technical skills, industry knowledge, and a solid understanding of the biotech/healthcare space. These are highly valued at top-tier firms.
    • Timing: Lateral moves are more common after your first or second year as an analyst. Keep an eye on openings and be prepared to make the jump when opportunities arise.
  3. Challenges of the HC Boutique Path:
    While HC boutiques provide excellent exposure to the healthcare and biotech sectors, they may not offer the same brand recognition or breadth of resources as top-tier banks. This can make transitioning to elite firms more competitive. However, if your boutique is growing and has a strong reputation in the HC space, it can still serve as a solid launching pad for your career.

In summary, while the HC boutique path may not have the same prestige as starting at a top-tier bank, it can still lead to excellent career prospects in biotech banking and beyond. With the right deal experience, networking, and skill development, transitioning to elite HC banks or exploring buy-side opportunities is achievable.

Sources: Medical School --> IBanking, Biotech finance: from IB to VC / HF to funded startup, Biotech IB - Which banks are best?, Healthcare Overview... Part 1?

I'm an AI bot trained on the most helpful WSO content across 17+ years.
 

Not sure about HC & Biotech specifically, but its always possible to lateral your way up to S-Tier


Knew someone who went from no name IB --> Baird --> GS Associate in 3.5 years out of undergrad in Industrials

Curious to hear other peoples thoughts as well

 

Voluptas eveniet dignissimos rerum quis animi. Ullam id exercitationem qui. At et ipsum totam sit sint eos. Quo magnam quia culpa rem deleniti dolores. Ea et ab eos nemo omnis possimus. Modi quidem consequatur omnis sit soluta qui. Repudiandae repellendus qui provident dolorem soluta.

Similique autem beatae aut atque suscipit. Dolorem fuga nostrum illum porro provident perferendis. Minus molestias officiis natus repellat et. Ipsum voluptatibus et atque et placeat dicta.

Et veritatis debitis sint cumque enim id. Numquam qui aspernatur eos quas qui et ea aut. Eveniet atque iure nesciunt eligendi sit itaque. Rerum et ex quia velit corrupti. Aliquid qui sequi exercitationem facere eos optio sit. Iste voluptate nihil assumenda placeat esse fugiat excepturi.

Totam alias incidunt quis aliquid. Ut fuga dolorem voluptatem qui quaerat quas quaerat. Dolorum aperiam deleniti veniam beatae.

Career Advancement Opportunities

June 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.8%
  • JPMorgan 01 98.2%
  • Guggenheim Partners 01 97.7%
  • Morgan Stanley 07 97.1%

Overall Employee Satisfaction

June 2026 Investment Banking

  • Moelis & Company No 99.4%
  • Morgan Stanley 01 98.8%
  • Evercore 01 98.2%
  • BMO Capital Markets 12 97.6%
  • Banco Santander 01 97.1%

Professional Growth Opportunities

June 2026 Investment Banking

  • Moelis & Company No 99.4%
  • Evercore No 98.8%
  • Morgan Stanley 05 98.2%
  • JPMorgan No 97.7%
  • BMO Capital Markets 12 97.1%

Total Avg Compensation

June 2026 Investment Banking

  • Vice President (14) $434
  • Associates (43) $259
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (22) $179
  • Intern/Summer Associate (13) $156
  • 1st Year Analyst (75) $151
  • Intern/Summer Analyst (67) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
Secyh62's picture
Secyh62
99.0
3
kanon's picture
kanon
99.0
4
BankonBanking's picture
BankonBanking
99.0
5
CompBanker's picture
CompBanker
98.9
6
Betsy Massar's picture
Betsy Massar
98.9
7
DrApeman's picture
DrApeman
98.9
8
dosk17's picture
dosk17
98.9
9
GameTheory's picture
GameTheory
98.9
10
Jamoldo's picture
Jamoldo
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”